AtriCure to Announce Second Quarter 2022 Financial Results

Rhea-AI Summary

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will release its second quarter 2022 financial results on August 2, 2022. An audio webcast will be held at 4:30 p.m. Eastern Time to discuss these results, accessible via AtriCure's investor page. The Isolator® Synergy™ Ablation System, the first FDA-approved device for persistent Afib, and the widely used AtriClip® devices showcase the company's innovation in Afib management. With over 33 million Afib patients globally, AtriCure continues to address related healthcare challenges.

Positive

• AtriCure’s Isolator® Synergy™ Ablation System is the first FDA-approved device for persistent Afib.
• AtriCure’s AtriClip® products are the most widely sold LAA management devices globally.
• The upcoming webcast on August 2 will provide insights into the company’s financial health.

Negative

• None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on Tuesday, August 2, 2022.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 2, 2022, to discuss its second quarter 2022 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the webcast will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005125/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure announce its Q2 2022 financial results?

AtriCure will announce its Q2 2022 financial results on August 2, 2022.

What is the significance of AtriCure's Isolator® Synergy™ Ablation System?

It is the first FDA-approved medical device for the treatment of persistent Afib.

How can investors access AtriCure's financial results webcast?

Investors can access the webcast on AtriCure’s corporate website at 4:30 p.m. Eastern Time on August 2, 2022.

What are the main products offered by AtriCure?

AtriCure offers the Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System.